Showing Results for: “type diabetes”

Exploratory Analysis from the SURPASS-4 Trial Data for Kidney Function with Tirzepatide Compared to Insulin Glargine A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk. SURPASS-4 was part of the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide. Findings were presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Chronic kidney disease (CKD)

This World Diabetes Day, Know Diabetes by Heart™ national spokespeople spotlight the link between type 2 diabetes and cardiovascular disease Today, on World Diabetes Day, the American Heart Association and the American Diabetes Association, two of the world’s leading health organizations in the areas of cardiovascular diseases and diabetes, announce new patient spokespeople for Know Diabetes by Heart ™ , a joint initiative to inspire more than 30 million Americans living with diabetes to lower their risk for cardiovascular death, heart attacks, heart failure and stroke. Five ambassadors and

The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now report on the extensive development of severe renal, cardiac, eye, nerve, and pregnancy complications in early adulthood in patients with youth-onset type 2 diabetes. Results from this follow up study, TODAY2, presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®, show an accelerating rate of serious complications within the last five years and point to the increased

The U.S. Food and Drug Administration (FDA) convened the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC) on May 27, 2021, to review Teplizumab, which has shown the ability to delay the onset of Type 1 diabetes symptoms by two years. The American Diabetes Association ® (ADA) applauds the FDA Advisory Committee’s approval of Teplizumab for those at risk for developing type 1 diabetes (T1D). Click here to view the official comments submitted by the ADA. In response, Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA shared the following: “This is undoubtedly

Results of NIDDK’s, Fuzzy Logic Automated Insulin Regulation (FLAIR) study showed increased time in range and improved A1C levels in adolescents and young adults who used system Medtronic’s Advanced Hybrid Closed-Loop system use in adolescents and young adults with type 1 diabetes (T1D) can lead to improved daytime blood sugar control without an increase in hypoglycemia, according to research presented today at the American Diabetes Association’s® (ADA’s) 80th Scientific Sessions. The presentation, “FLAIR—An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G

As part of our commitment to reduce the incidence of diabetes, we are working with the Centers for Disease Control and Prevention (CDC)’s National Diabetes Prevention Program (National DPP) to implement a key feature of the program—a research-based, structured lifestyle change program that is proven to help prevent and delay the development of type 2 diabetes. Before people develop type 2 diabetes, they almost always have prediabetes —where blood glucose (also called blood sugar) levels are higher than normal but not yet high enough to be diabetes. Prediabetes is very common. Approximately 88

Read more on the warning signs, symptoms of diabetes, prediabetes, type 1 & 2 symptoms, type 2 risk test, different ways diabetes is diagnosed.

Update on SCORED and SOLOIST trials shows reduction in cardiovascular events and stroke using glucose-lowering agents Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 (SGLT2) and sodium-glucose transport protein 1 (SGLT1) in reducing heart failure, heart attack, and stroke—major problems in people with diabetes. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with diabetes are at an increased risk of life-threatening

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized